BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

No Major Heart Risk Seen in New Psoriasis Drugs, Baylor Research Institute Study


8/24/2011 7:26:45 AM

A new, highly effective class of psoriasis drugs did not appear to raise the risk of heart problems in a review of published studies, but the analysis may not have been big enough to detect rare cases, U.S. researchers said. Abbott Laboratories pulled its U.S. and European marketing applications for one of the drugs in January, known as briakinumab [ID:nN14150334], due to concerns raised by U.S. regulators. The drug is part of a new class of treatments known as anti-IL-12/23 agents that have been shown to be highly effective at treating psoriasis, an autoimmune disease marked by well-defined patches of red raised skin.

Read at Reuters
Read at News Release
Read at HealthDay
Read at EurekAlert!

   
Psoriasis

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES